Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24924079 | 0.90 | CYP11B2 (0.56) | CYP11B2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL26422507 | 0.83 | CYP11B2 (0.58) | CYP11B2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18706042 | 0.81 | MAPT (0.46) | CYP11B2THRBMAPT | |
| SCHEMBL18705865 | 0.80 | ESR2 (0.46) | CYP11B2KDM4ELMNAMAPTCYP2C19 | |
| Hydrochloric Acid SCHEMBL9482313 | 0.80 | MAPT (0.55) | ALDH1A1MEN1KMT2ACYP3A4LMNA | |
| SCHEMBL13453993 | 0.80 | MAPT (0.60) | CYP11B2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL25344786 | 0.80 | ESR2 (0.46) | CYP11B2KDM4ELMNAMAPTCYP2C19 | |
| SCHEMBL746253 | 0.80 | CYP11B2 (0.65) | CYP11B2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL714527 | 0.79 | MAPT (0.59) | ALDH1A1MEN1KMT2ACYP3A4LMNA | |
| SCHEMBL715591 | 0.79 | MAPT (0.59) | ALDH1A1MEN1KMT2ACYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
| EP-2451285-B1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2451285-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| WO-2011005608-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005608-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-5849764-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0871624-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997021703-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| EP-0510028-A1 | THIOFORMAMIDE DERIVATIVES. | RHONE POULENC RORER SA (FR) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | CYP11B2 4526/4885ALDH1A1 3004/4885MEN1 4516/4885 |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | CYP11B2 2131/4885ALDH1A1 373/4885MEN1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.